Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study – CNBC

By
Internationalfinancialnews.com
-
0
165


  1. Eli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study  CNBC
  2. Eli Lilly’s tirzepatide cuts heart failure risks, company says  NBC News
  3. Live news: 10-year Treasury yield dips under 4% as traders bet on three Fed rate cuts in 2024  Financial Times
  4. Video Study suggests Zepbound can help patients dealing with heart failure  ABC News
  5. Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity  Investors | Eli Lilly and Company


LEAVE A REPLY

Please enter your comment!
Please enter your name here